Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Proximod Tablets in Moderate-to-Severe Active Rheumatoid Arthritis Subjects With Inadequate Response or Intolerance to bDMARDs and/or tsDMARDs

NCT07856511 is registered in ClinicalTrials.gov with Jiankuan (Suzhou) Biotechnology Company Limited as lead sponsor.

NCT NCT07856511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07856511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Proximod Tablets in Moderate-to-Severe Active Rheumatoid Arthritis Subjects With Inadequate Response or Intolerance to bDMARDs and/or tsDMARDs
Lead sponsor
Jiankuan (Suzhou) Biotechnology Company Limited
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
September 30, 2028
Enrollment
590 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthrits